Researchers at UVA developed an AI imaging tool using PET/MR to distinguish treatment effects from tumor progression in glioblastoma patients.
Key Details
- 1AI tool analyzes PET/MR imaging findings in glioblastoma cases.
- 2Distinguishes between tissue changes due to treatment vs. tumor progression.
- 3Current monitoring approaches often require a waiting period of 3+ months.
- 4Faster distinction could enable earlier treatment modification for recurrence.
- 5Method developed by a University of Virginia team.
Why It Matters
Improved differentiation between treatment effects and recurrence could allow clinicians to adjust therapies more quickly, potentially improving outcomes for a highly aggressive brain cancer. This underlines the growing significance of AI-assisted multi-modal imaging in oncology workflows.
Source
Health Imaging
Related News
•Radiology Business
Stanford and Rad Partners Propose Framework for Evaluating Radiology AI Models
Stanford and Rad Partners developed a structured framework for pre-deployment evaluation of radiology AI models to guide purchasing decisions.
•Cardiovascular Business
Radiology Leads in FDA-Cleared Imaging AI Algorithms, Cardiology Surges
Radiology maintains its lead as the specialty with the most FDA-cleared AI algorithms, while cardiology now surpasses 200 cleared tools.
•AuntMinnie
Deep Learning CT Muscle Segmentation Enhances Sarcopenia Detection in COPD
A deep learning model for CT-based 3D pectoralis muscle segmentation outperforms standard 2D techniques in assessing muscle loss among COPD patients.